SBIO (ALPS Medical Breakthroughs ETF) Stock Analysis - Hedge Fund Holdings

ALPS Medical Breakthroughs ETF (SBIO) is a publicly traded the market company. As of May 21, 2026, SBIO trades at $58.43 with a market cap of $0 and a P/E ratio of 0.00. SBIO moved +0.00% today. Year to date, SBIO is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces SBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SBIO stock?

Hedge funds tracked by Rallies that own SBIO include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ALPS Medical Breakthroughs ETF.

SBIO Key Metrics

Key financial metrics for SBIO
MetricValue
Price$58.43
Market Cap$0
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$0.00
52-Week Low$0.00
Volume114.58K
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Top Hedge Funds Holding SBIO

  • Citadel Advisors holds 14.99K shares of SBIO, changed +36.23% as of Dec 31, 2024.

SBIO Analyst Consensus

SBIO analyst coverage data. Average price target: $0.00.

Common questions about SBIO

Who owns SBIO stock?
Hedge funds tracked by Rallies that own SBIO include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ALPS Medical Breakthroughs ETF.
Does Rallies show 13F holders for SBIO?
Yes. Rallies tracks hedge fund and 13F ownership data for SBIO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SBIO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SBIO. It does not provide personalized investment advice.
SBIO

SBIO